11:38 PM GMT, Jul 11, 2008
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact firstname.lastname@example.org.
Momenta gains on Copaxone challenge
Momenta (NASDAQ:MNTA) gained $0.81 to $13.89 on Friday after FDA accepted for review
Read the full 134 word article